As­traZeneca scores an­oth­er in­dus­try vic­to­ry over the fed­er­al gov­ern­ment in 340B lit­i­ga­tion

The US dis­trict court of Delaware hand­ed As­traZeneca a vic­to­ry late Wednes­day, ef­fec­tive­ly set­ting aside a vi­o­la­tion let­ter sent by Pres­i­dent Biden’s Health Re­sources and Ser­vices Ad­min­is­tra­tion for the com­pa­ny’s fail­ure to com­ply with its oblig­a­tions un­der a fed­er­al pro­gram pro­vid­ing low-in­come in­di­vid­u­als with less ex­pen­sive drugs.

The fa­vor­able opin­ion for As­traZeneca again cuts in­to HRSA’s in­ter­pre­ta­tion of the statute re­lat­ed to the pro­gram, known as 340B, which has been up­end­ed by more than a dozen bio­phar­ma com­pa­nies which have placed re­stric­tions around of­fer­ing the cheap­er prices to an un­lim­it­ed num­ber of con­tract phar­ma­cies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER